Translate

Thursday, July 31, 2014

جريمة في وضح الليل

  •  
  •  
1 آب 2014
كالتلذّذ الساديّ. 
كالتعذيب الواعي. 
المنهجي. 
المقصود.
 كالقتل العلني.

هذا هو الموتُ المسموحُ به في المستشفى، عندما يعجز الطبّ.
لَشيءٌ لا يُحتَمَل أن يكون المرء شاهداً على موتٍ علميّ، قانونيّ، هادئ، بطيء، ومحتوم، كهذا.

لا أريد لأحدٍ ما أن يشهد على شيءٍ متوحّشٍ كهذا.
 فكيف إذا كان هذا الـ"أحد" شخصاً "طبيعياً" و"عاطفياً"! كيف إذا كنتَ أنتَ نفسكَ؛ الإبن أو الإبنة؛ الشقيق أو الشقيقة؛ الأب أو الأمّ؛ الحفيد أو الحفيدة؛ تشهد على هذا القتل المعلَن في الليل الاستشفائيّ الراضخ لكلّ جريمةٍ من هذا النوع؟
أقانونيٌّ؟ أأخلاقيٌّ؟ أطبيعيٌّ، أن يحدث مثل هذا؟! حتى لأسأل في الليل المتحشرج: أإلهيٌّ، هو هذا القتل المعذِّب؟!

لا أتّهم أحداً بالطبع. 
ولا أحاكم أحداً.
 لكن، ها أجدني أسأل هذا السؤال الأخلاقيّ القانونيّ: أيهما قتلٌ؛ القتل الرحيم، أم هذا الذي تشهده بحواسكَ جميعها، وبالعقل، وبالقلب، عارفاً المعرفةَ العلمية والطبية، وبلسان العقل، أن لا سبيل إلى الخلاص من هذا المصير، بسوى القتل النبيل الذي يشرِّف الأخلاق الطبية و... الإلهية؟!
* * *

أُعطيتُ نعمةَ (!) أن أشهد، مع شقيقات إلهيّات لي، على تعذيبٍ كهذا طوال ليلتَين متواليتَين. كان الموت، موت الوالدة، ليكون طبيعياً، مقنعاً، وحتمياً، بسبب انهيار وظائف الجسد.
 لكن وعي الجسد لحياته ولموته كان أقوى.
لم يوفّر الجسمُ الطبيّ وسيلةً طبية، "قانونية" و"أخلاقية"، إلاّ استخدمها.
 لكن الجسد المحشرِج كان يأبى الرضوخ لهذا الحدّ "القانوني"، "الأخلاقي". وكم سمعتُه كان يصرخ، من دون كلام: أغيثوني بشيءٍ "أكثر"، "أقوى"، "أعنف"، "أعمق"؛ شيءٍ يمحو الصراخ برمّته، يخنقه، ويمنح ليل السرير، والغرفة، والمستشفى، أن ينام في صمته العميم.

في حالاتٍ مقنّنة، ومحدّدة، كهذه، لماذا لا تنفسح الأبواب أمام الموت لتسهيل عبوره، ولإمراره إمراراً أخلاقياً، خالياً من التعذيب؟!

كم يعزّيني من الآن أن أكتب للجميع، كوصية، كإنذار: افتحوا الأبواب أمام موتي، عندما يأتي الوقت، لتسهيل عبور هذا الموت. وهو يأتي، بالطبع، عندما يقف الطبّ عاجزاً لدى انهيار وظائف الجسد، وأمام إسكات العذاب.
كلّ مَن لا يطبّق هذه الوصية يكون ملعوناً عندي إلى الأبد.

كم يعزّيني، من الآن، أن ينوب هذا الحبرُ صارخاً باسمي مسبقاً، عندما لن يعود في مقدوري أن أصرخ بالكلمات: عدم السماح لمثل هذا القتل الرحيم هو قتلٌ واعٍ، مقصود، ومطلق. كالقتل الذي يوازي الجريمة الموصوفة.

خذوا كلامي بمثابة إخبار، ما دمتُ لم أستطع أن أفعل شيئاً أمام جريمة ارتُكِبت في وضح النهار. بل في وضح الليل!

Wednesday, July 30, 2014

XARTEMIS™ XR is the first and only FDA-approved combination of oxycodone and acetaminophen to provide immediate- and extended-release analgesia.1
  • Delivers onset of pain relief in less than an hour and lasts up to 12 hours with a predictable pharmacokinetic profile.1,3
    • In the clinical trial, supplemental analgesia was available to patients in the XARTEMIS XR and placebo groups.1
    • Supplemental ibuprofen was used by less than 50% of the XARTEMIS XR-treated patients after the first dose interval.1
  • Simple dosing—2 tablets, twice daily.1
    • On the first day of treatment, the second dose may be taken at 8 hours after initial dose if pain intensity requires it.
    • Contains 7.5 mg of oxycodone HCl and 325 mg of acetaminophen per tablet.
IMPORTANT RISK INFORMATION
XARTEMIS XR tablets should be swallowed whole one at a time, with enough water to ensure complete swallowing immediately after placing in mouth. Do not break, chew, crush, cut, dissolve or split the tablets.
Release Date: April 8, 2014
Expiration Date: April 8, 2015

Co-Chairs

  • Timothy R. Deer, MD

    President and Chief Executive Officer
    Center for Pain Relief
    Charleston, West Virginia
  • Richard L. Rauck, MD

    Clinical Associate Professor
    Department of Anesthesiology
    Wake Forest University School of Medicine
    Winston-Salem, North Carolina

Goal

The goal of this program is to educate clinicians about the current landscape in intrathecal (IT) therapy in the treatment of severe chronic pain and to provide useful information on referring patients for this therapy or using this therapy.

Learning Objectives

At the completion of this activity, participants should be better able to:
  1. Describe the advantages of delivering medication to the site of action.
  2. Identify patients who are most likely to benefit from IT therapy and ways to find health care professionals who provide IT therapy.
  3. Discuss the IT medications currently on the market, including trialing, dose titration, and maintenance using ziconotide therapy with implanted pumps.
  4. Review the tolerability and safety of IT therapy, including management of adverse events for both IT ziconotide and IT morphine.

Intended Audience

Physicians who treat pain, including anesthesiologists and pain specialists.

Statement of Need

Education on the appropriate use of IT therapy for chronic pain is necessary based on the following practice gaps, which were identified via needs assessment, including a comprehensive literature review:
  • Clinicians may not be familiar with relatively recent studies on the usefulness of IT therapy.
  • There is a relative paucity of literature to guide clinicians with respect to patient selection and referrals to other clinicians who can provide IT therapy.
  • Because a number of medications are used in IT therapy, but only 2 are FDA-approved for this use, clinicians need education on availability and proper use.
  • Clinicians may not be aware of the tolerability and safety profiles of IT medications, and how to manage adverse events.

Estimated Time for Completion

1 hour

Course Format

Monograph

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group and Applied Clinical Education. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

To receive CME credit, participants should read the preamble, read the monograph, and visit www.cmezone.com/intrathecal to complete the online post-test and activity evaluation. CME certificates will be made available immediately upon successful completion.

Fees

There are no fees for participating in or receiving credit for this activity.

Disclosure of Conflicts of Interest

Global Education Group requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are vetted thoroughly by Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:
  • Timothy R. Deer, MD: Flowonix, Jazz Pharmaceuticals, Medtronic (consultant/independent contractor); Medtronic (grant/research support); Jazz Pharmaceuticals (speakers' bureau)
  • Richard L. Rauck, MD: Jazz Pharmaceuticals, Mallinckrodt, Medtronic (consultant/independent contractor; grant/research support); Jazz Pharmaceuticals (honoraria, speakers' bureau)
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:
  • George Ochoa: Nothing to disclose
  • Jennifer Kulpa: Nothing to disclose
  • A shley Marostica, RN , MSN : Nothing to disclose
  • A manda Glazer, PhD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Applied Clinical Education do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or courses of diagnosis or treatment discussed should not be used by clinicians without evaluation of patient conditions, contraindications, applicable manufacturer’s product information, and the recommendations of other authorities.

Accreditor Contact Information

For information about the accreditation of this program, please contact Global Education Group at (303) 395-1782 or inquire@globaleducationgroup.com.

System Requirements

PC
  • Microsoft Windows 2000 SE or greater
  • Flash Player Plugin (v7.0.1.9 or greater)
  • Internet Explorer (v5.5 or greater) or Firefox Adobe Acrobat Reader
MAC
  • MAC OS 10.2.8 Flash Player Plugin (v7.0.1.9 or greater)
  • Safari Adobe Acrobat Reader
  • Internet Explorer is not supported on the Macintosh




Naloxegol Shows Efficacy Against Multiple Symptoms of Opioid-Induced Constipation in Phase III Trials
 
San Diego—Naloxegol, an oral, peripherally acting μ-opioid receptor antagonist, appears safe and effective in relieving opioid-induced constipation (OIC).

OIC occurs in 40% to 60% of individuals taking opioids, and is a unique form of constipation, said William D. Chey, MD, who presented the findings of two identical, randomized controlled, Phase III trials of naloxegol at the ACG meeting. It can become so problematic that some patients choose to forego their pain medicine, leading to a significant negative effect on their quality of life.
“The study objectives were to evaluate the safety and efficacy of naloxegol in two doses versus placebo in patients taking opioids for noncancer pain,” said Dr. Chey, professor of medicine at the University of Michigan Health System in Ann Arbor.
The primary outcome of the two trials—KODIAC-04 and KODIAC-05—was greater than three spontaneous bowel movements (SBMs) per week, with an increase of more than one SBM per week over baseline for at least nine of the 12 randomization weeks, and for at least three of the four final weeks.
“In addition to this was the requirement of demonstrating symptom improvement for at least one of the following: straining, stool consistency and number of days with a complete spontaneous bowel movement,” Dr. Chey said. “We tend to focus on stool frequency, but like constipation in general, OIC is associated with alterations in a variety of other symptoms, including straining, hard stools and a sense of incomplete evacuation.”
The study population comprised patients aged 18 to 85 years with OIC who had been taking between 30 and 1,000 mg of oral morphine for noncancer pain for at least four weeks before the study period. About 65% of these patients had failed to respond to treatment with one or more laxatives before enrollment in the study.
During a two-week screening period, patients were required to have active symptoms of OIC, defined as fewer than three SBMs per week and at least one symptom of hard lumpy stools; straining; or a sensation of incomplete evacuation more than 25% of the time. This was followed by a two-week confirmation period during which patients had to experience the symptoms previously described, documented by e-diary, to qualify for the trial.
Roughly 700 patients completed the qualification and were enrolled in the two trials. The patients, who were similar in terms of demographics and constipation-related symptoms, were randomized to receive 12 weeks of treatment with naloxegol at one of two doses, 12.5 or 25 mg, or placebo. The differences between the groups in each of the two studies were analyzed by the Cochran-Mantel-Haenszel comprehensive test stratified by response to laxatives at baseline. About 80% of the patients completed the trial.
In both trials, the higher dose of the drug resulted in improvement in the primary end point compared with placebo, even after symptoms beyond stool frequency were incorporated into the response. Additionally, in both trials, the higher dose was associated with statistically significant therapeutic gains of 10% to 15% in other symptoms of OIC (e.g., straining) compared with placebo. In the KODIAC-04 trial, the lower dose was associated with a statistically significant benefit over placebo in terms of meeting the primary end point; this was not seen in the KODIAC-05 trial.
Serious adverse events (AEs) and AEs were rare and were observed equally at both dose levels of naloxegol. The more commonly reported AEs, abdominal pain and diarrhea, were dose-dependent. Discontinuation of treatment occurred more often in the 25-mg group.
“To conclude, naloxegol was efficacious over 12 weeks of treatment for noncancer pain patients with OIC; efficacy was demonstrated with the 25-mg dose in both of these large, randomized Phase III studies,” Dr. Chey said.
The results presented by Dr. Chey and his colleagues are especially important “because they indicate not only that naloxegol has the potential to increase bowel movement frequency in OIC, but also to improve the associated symptoms that patients find so distressing,” said Brooks D. Cash, MD, professor of medicine at the University of South Alabama, in Mobile.


Naloxegol Shows Efficacy Against Multiple Symptoms of Opioid-Induced Constipation in Phase III Trials

 
San Diego—Naloxegol, an oral, peripherally acting μ-opioid receptor antagonist, appears safe and effective in relieving opioid-induced constipation (OIC).

OIC occurs in 40% to 60% of individuals taking opioids, and is a unique form of constipation, said William D. Chey, MD, who presented the findings of two identical, randomized controlled, Phase III trials of naloxegol at the ACG meeting. It can become so problematic that some patients choose to forego their pain medicine, leading to a significant negative effect on their quality of life.
“The study objectives were to evaluate the safety and efficacy of naloxegol in two doses versus placebo in patients taking opioids for noncancer pain,” said Dr. Chey, professor of medicine at the University of Michigan Health System in Ann Arbor.
The primary outcome of the two trials—KODIAC-04 and KODIAC-05—was greater than three spontaneous bowel movements (SBMs) per week, with an increase of more than one SBM per week over baseline for at least nine of the 12 randomization weeks, and for at least three of the four final weeks.
“In addition to this was the requirement of demonstrating symptom improvement for at least one of the following: straining, stool consistency and number of days with a complete spontaneous bowel movement,” Dr. Chey said. “We tend to focus on stool frequency, but like constipation in general, OIC is associated with alterations in a variety of other symptoms, including straining, hard stools and a sense of incomplete evacuation.”
The study population comprised patients aged 18 to 85 years with OIC who had been taking between 30 and 1,000 mg of oral morphine for noncancer pain for at least four weeks before the study period. About 65% of these patients had failed to respond to treatment with one or more laxatives before enrollment in the study.
During a two-week screening period, patients were required to have active symptoms of OIC, defined as fewer than three SBMs per week and at least one symptom of hard lumpy stools; straining; or a sensation of incomplete evacuation more than 25% of the time. This was followed by a two-week confirmation period during which patients had to experience the symptoms previously described, documented by e-diary, to qualify for the trial.
Roughly 700 patients completed the qualification and were enrolled in the two trials. The patients, who were similar in terms of demographics and constipation-related symptoms, were randomized to receive 12 weeks of treatment with naloxegol at one of two doses, 12.5 or 25 mg, or placebo. The differences between the groups in each of the two studies were analyzed by the Cochran-Mantel-Haenszel comprehensive test stratified by response to laxatives at baseline. About 80% of the patients completed the trial.
In both trials, the higher dose of the drug resulted in improvement in the primary end point compared with placebo, even after symptoms beyond stool frequency were incorporated into the response. Additionally, in both trials, the higher dose was associated with statistically significant therapeutic gains of 10% to 15% in other symptoms of OIC (e.g., straining) compared with placebo. In the KODIAC-04 trial, the lower dose was associated with a statistically significant benefit over placebo in terms of meeting the primary end point; this was not seen in the KODIAC-05 trial.
Serious adverse events (AEs) and AEs were rare and were observed equally at both dose levels of naloxegol. The more commonly reported AEs, abdominal pain and diarrhea, were dose-dependent. Discontinuation of treatment occurred more often in the 25-mg group.

“To conclude, naloxegol was efficacious over 12 weeks of treatment for noncancer pain patients with OIC; efficacy was demonstrated with the 25-mg dose in both of these large, randomized Phase III studies,” Dr. Chey said.
The results presented by Dr. Chey and his colleagues are especially important “because they indicate not only that naloxegol has the potential to increase bowel movement frequency in OIC, but also to improve the associated symptoms that patients find so distressing,” said Brooks D. Cash, MD, professor of medicine at the University of South Alabama, in Mobile.

Monday, July 28, 2014



Euthanasia and assisted suicide: a physician’s
and ethicist’s perspectives


Medicolegal and Bioethics
Dovepress
J Donald Boudreau1Margaret A Somerville2
1Faculty of Medicine, Department of Medicine, McGill University, Montreal, QC, Canada; 2Faculty of Law, Faculty of Medicine, and Centre for Medicine, Ethics and Law, McGill University, Montreal, QC, Canada
Correspondence: J Donald Boudreau
Center for Medical Education, Faculty
of Medicine, McGill University,
1110 Pine Ave West, Montreal,
QC, H3A 1A3, Canada
Tel +1 514 398 5613
Fax +1 514 398 7246
Email donald.boudreau@mcgill.ca

Abstract: The debate on legalizing euthanasia and assisted suicide has a broad range of participants including physicians, scholars in ethics and health law, politicians, and the general public.
 It is conflictual, and despite its importance, participants are often poorly informed or confused. It is essential that health care practitioners are not among the latter. This review responds to the need for an up-to-date and comprehensive survey of salient ethical issues. Written in a narrative style, it is intended to impart basic information and review foundational principles helpful in ethical decision-making in relation to end-of-life medical care. 
The authors, a physician and an ethicist, provide complementary perspectives. They examine the standard arguments advanced by both proponents and opponents of legalizing euthanasia and note some recent legal developments in the matter. They consider an aspect of the debate often underappreciated; that is, the wider consequences that legalizing euthanasia might have on the medical profession, the institutions of law and medicine, and society as a whole. The line of argument that connects this narrative and supports their rejection of euthanasia is the belief that intentionally inflicting death on another human being is inherently wrong. Even if it were not, the risks and harms of legalizing euthanasia outweigh any benefits. Ethical alternatives to euthanasia are available, or should be, and euthanasia is absolutely incompatible with physicians’ primary mandate of healing.
Keywords: euthanasia, physician assisted-suicide, healing, suffering, palliative care, palliative sedation

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.

CMAJ. 2010 Oct 5;182(14):E694-701.

Abstract

BACKGROUND:

Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood.

METHODS:

Adults with post-traumatic or postsurgical neuropathic pain were randomly assigned to receive cannabis at four potencies (0%, 2.5%, 6% and 9.4% tetrahydrocannabinol) over four 14-day periods in a crossover trial. Participants inhaled a single 25-mg dose through a pipe three times daily for the first five days in each cycle, followed by a nine-day washout period. Daily average pain intensity was measured using an 11-point numeric rating scale. We recorded effects on mood, sleep and quality of life, as well as adverse events.

RESULTS:

We recruited 23 participants (mean age 45.4 [standard deviation 12.3] years, 12 women [52%]), of whom 21 completed the trial. The average daily pain intensity, measured on the 11-point numeric rating scale, was lower on the prespecified primary contrast of 9.4% v. 0% tetrahydrocannabinol (5.4 v. 6.1, respectively; difference = 0.7, 95% confidence interval [CI] 0.02-1.4). Preparations with intermediate potency yielded intermediate but nonsignificant degrees of relief. Participants receiving 9.4% tetrahydrocannabinol reported improved ability to fall asleep (easier, p = 0.001; faster, p < 0.001; more drowsy, p = 0.003) and improved quality of sleep (less wakefulness, p = 0.01) relative to 0% tetrahydrocannabinol. We found no differences in mood or quality of life. The most common drug-related adverse events during the period when participants received 9.4% tetrahydrocannabinol were headache, dry eyes, burning sensation in areas of neuropathic pain, dizziness, numbness and cough.

CONCLUSION:

A single inhalation of 25 mg of 9.4% tetrahydrocannabinol herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep and was well tolerated. Further long-term safety and efficacy studies are indicated. 

(International Standard Randomised Controlled Trial Register no. ISRCTN68314063).

Friday, July 25, 2014

Long-Term Central Venous Catheter Use and Risk of Infection in Older Adults With Cancer

+ Author Affiliations
  1. All authors: Memorial Sloan Kettering Cancer Center, New York, NY.
  1. Corresponding author: Allison Lipitz-Snyderman, PhD, Center for Health Policy and Outcomes, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 300 East 66th St, 14th Floor, New York, NY 10065; e-mail: snyderma@mskcc.org

Abstract© 2014 by American Society of Clinical Oncology

Purpose Long-term central venous catheters (CVCs) are often used in patients with cancer to facilitate venous access to administer intravenous fluids and chemotherapy. CVCs can also be a source of bloodstream infections, although this risk is not well understood. We examined the impact of long-term CVC use on infection risk, independent of other risk factors such as chemotherapy, in a population-based cohort of patients with cancer.
Patients and Methods We conducted a retrospective analysis using SEER-Medicare data for patients age > 65 years diagnosed from 2005 to 2007 with invasive colorectal, head and neck, lung, or pancreatic cancer, non-Hodgkin lymphoma, or invasive or noninvasive breast cancer. Cox proportional hazards regression was used to examine the relationship between CVC use and infections, with CVC exposure as a time-dependent predictor. We used multivariable analysis and propensity score methods to control for patient characteristics.
Results CVC exposure was associated with a significantly elevated infection risk, adjusting for demographic and disease characteristics. For patients with pancreatic cancer, risk of infections during the exposure period was three-fold greater (adjusted hazard ratio [AHR], 2.93; 95% CI, 2.58 to 3.33); for those with breast cancer, it was six-fold greater (AHR, 6.19; 95% CI, 5.42 to 7.07). Findings were similar when we accounted for propensity to receive a CVC and limited the cohort to individuals at high risk of infections. 

Conclusion 
Long-term CVC use was associated with an increased risk of infections for older adults with cancer. Careful assessment of the need for long-term CVCs and targeted strategies for reducing infections are critical to improving cancer care quality.

Footnotes

  • Supported by Cancer Center Support Grant No. P30 CA 008748.
  • Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Skybridge

  1. Kevin P. Eaton
+ Author Affiliations
  1. From the Baylor College of Medicine, Houston, TX.
  1. Corresponding author: Kevin P. Eaton, MD, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030; e-mail: kpeaton@bcm.edu.
The expanse of America collapses here in this medical center. When a surgeon opens a calcified artery, salt pours from dry bulk containers on Long Beach. When kids play basketball in Jackson Park, hearts beat again with every dribble. Each building is a different city. Skybridges take us all across America, coast to coast in just one afternoon.
She wanted to go to San Francisco. A new grandmother, she told me. Her PET scan mapped the power grid along the East Coast, now dusk.
A shortcut, I told her, to beat the setting sun. I hugged her at the door, and through falling tears, she melted like watercolor over the sun-painted skybridge– the one coursing through the Sierra Nevada as it crosses over Main Street. She'd be West before I could close her chart, before I would stop waving.

أطفال فلسطين

المطران جورج خضر

26 تموز 2014
هذا ليس مقال حسرة لأن قتل اليهود لنا لا يذهلني. هذا تاريخهم. ليس أنهم ملعونون. الجريمة ليست مفروضة عليك من قدر. تختارها لأنك تحت اللعنة، لأنها سرك وليس علينا أن نفهم. جرحي أنا أنّ أولاد فلسطين يُقتلون (بضمّ الياء) وليس من سبب الا أن المجرم مجرم وأنا لست الله لأبرره. لماذا تباد فلسطين أمام أعين كل الشعوب؟ لماذا قُتل (بضمّ القاف) يسوع الذي كان من الناصرة؟ ماذا يبقى من العالم إن ذهبت فلسطين؟ إن هي ذهبت فهذا قتل آخر ليسوع الناصري. ويسوع أهم شيء في العالم. إن ذهبت فلسطين أين أقبّل قدمي يسوع؟ أنا في حاجة الى أطفال فلسطين أني في حاجة الى قدمي يسوع.
أنا واثق من أن الذين لا يحبون فلسطين لكونهم تهوّدوا لا يحبون يسوع المسيح. أنت لا تستطيع أن تحب ابن مريم ما لم تحبّ بلدها. فلنصالح الأرض حتى نصالح سيد الأرض. أذكر أني لما كنت في سيارة داخلاً يافا من لبنان السنة الـ1946 صلبت وجهي (أي رسمت على وجهي إشارة الصليب) لأن يافا عندي كانت القدس والقدس كانت العالم. كيف أترك فلسطين ولا أترك مريم؟ لا تسيسوا الموضوع. ماذا تريدون مني عندما تقولون لي لماذا تتكلم عن فلسطين. أتريدون الحقيقة؟ فلسطين تعني لي يسوع الناصري. دمه انسكب على هذه الأرض من خشبة الصليب. طبعًا انسكب على العالم ولكن من القدس.

لا أستطيع أن أعزل دم فلسطين عن دم يسوع. أنا مع فلسطين الجريحة لأني آتٍ من جنبه. أنت لست عادلاً يا ابن الغرب إن حزنت على دم اليهود يراق ولم تحزن على أي دم آخر. من لا يعرف مساواة الدماء لا يعرف شيئًا. أنا عشت في الغرب طويلاً ولم أفهم أنهم كانوا يحزنون لعذاب اليهود ولا يحزنون على قوم آخرين. هل في الموت معسكر لليهود ومعسكر لغير اليهود؟ الكراهية للعرب ليست فقط سياسة. إنها خطيئة إذ ليس من خطيئة مبدعة. أنا لا أطلب منك أن تحب العرب على اليهود. أريدك أن تعدل. هذا هو شرط المحبة التي من الله. أريدك أن تحب اليهود لا الصهيونية. أنا كاتب هذا المقال أحبّ منهم من ليس عدواً ليسوع المسيح وأتمنى لو جعلوه حبيبهم. هذا هو الفارق بين اليهود والمسلمين.


إن المسلمين يحبون المسيح ويعرفونه نبياً لهم واليهود لا يعرفونه. سؤالنا الوحيد ليهود اليوم هو هل صرتم مع يسوع الناصري بعد أن قتلتموه أم لا تزالون أعداء؟
المسلمون يقولون إنه حبيبنا. وأنا لا أستطيع أن أساوي بين محبي يسوع وغير محبيه. لذلك كل هذه القربى بين مسيحيي الغرب واليهود عندي لا معنى لها. ولذلك كان السؤال هل اليهود يحبون مسيحيي الغرب كما هؤلاء يحبونهم؟ أطرح هنا سؤالاً لاهوتياً لا سؤالاً مجتمعياً. شعوري أن مسيحيي الغرب يحبون أن يقيموا في سذاجتهم ليظنوا أن اليهود يبادلونهم المحبة. المسيحيون عندهم أساس لاهوتي ليحبوا اليهود. هذا في ديانتهم. 


ولكن ما الأساس اللاهوتي عند اليهود ليبادلوهم المحبة؟
JE VOUS DEMANDE
Photo

Saturday, July 19, 2014

http://fr.slideshare.net/JennyStory/religion-and-spirituality-in-palliative-care?related=1

 http://fr.slideshare.net/JennyStory/religion-and-spirituality-in-palliative-care?related=1





How can we improve outcomes for patients and families under palliative care? implementing clinical audit for quality improvement in resource limited settings


King's College London, Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, Bessemer Road, Denmark Hill, London SE5 9PJ, United Kingdom

Date of Web Publication11-May-2010
Correspondence Address:
Lucy Selman
King's College London, Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, Bessemer Road, Denmark Hill, London SE5 9PJ
United Kingdom
Login to access the Email id



Get Permissions

 » Abstract 
Palliative care in India has made enormous advances in providing better care for patients and families living with progressive disease, and many clinical services are well placed to begin quality improvement initiatives, including clinical audit. Clinical audit is recognized globally to be essential in all healthcare, as a way of monitoring and improving quality of care. However, it is not common in developing country settings, including India. Clinical audit is a cyclical activity involving: identification of areas of care in need of improvement, through data collection and analysis utilizing an appropriate questionnaire; setting measurable quality of care targets in specific areas; designing and implementing service improvement strategies; and then re-evaluating quality of care to assess progress towards meeting the targets. Outcome measurement is an important component of clinical audit that has additional advantages; for example, establishing an evidence base for the effectiveness of services. In resource limited contexts, outcome measurement in clinical audit is particularly important as it enables service development to be evidence-based and ensures resources are allocated effectively. Key success factors in conducting clinical audit are identified (shared ownership, training, managerial support, inclusion of all members of staff and a positive approach). The choice of outcome measurement tool is discussed, including the need for a culturally appropriate and validated measure which is brief and simple enough to incorporate into clinical practice and reflects the holistic nature of palliative care. Support for clinical audit is needed at a national level, and development and validation of an outcome measurement tool in the Indian context is a crucial next step.

Keywords: Audit, Outcomes, Quality improvement, Quality of care

How to cite this article:
Selman L, Harding R. How can we improve outcomes for patients and families under palliative care? implementing clinical audit for quality improvement in resource limited settings. Indian J Palliat Care 2010;16:8-15

How to cite this URL:
Selman L, Harding R. How can we improve outcomes for patients and families under palliative care? implementing clinical audit for quality improvement in resource limited settings. Indian J Palliat Care [serial online] 2010 [cited 2014 Jul 20];16:8-15. Available from: http://www.jpalliativecare.com/text.asp?2010/16/1/8/63128



 » Introduction Top


Palliative care in resource-poor settings has made enormous advances in providing better care for patients and families living with progressive disease. Now that innovative, sustainable palliative care facilitates are in place in India, these clinical services are well placed to begin considering how to implement simple ways to strive for quality improvement. Clinical audit * is recognized globally to be essential in all healthcare, enabling quality of care to be monitored and improved. While clinical audit is common within palliative care in the developed world, it is far less common in developing country settings, including India. [1]

In this article we outline some of the reasons why clinical audit is so important in palliative care, and make suggestions for how Indian palliative care services can successfully engage with the audit process. Many of our suggestions come out of experience managing the Encompass study (2006-2008), during which the first clinical audit of palliative care services in sub-Saharan Africa was conducted. Working with principal investigators and local research nurses at four palliative care services in South Africa and one in Uganda, we developed a model for palliative care clinical audit in developing country settings which may be relevant to the Indian setting.

Here, we aim to introduce the concept of clinical audit within the palliative care setting, and share some of the lessons learnt during that project.


 » Measuring Quality in Healthcare Top


The quality of a healthcare system (or organization) relates to how effective that system or organization is in achieving it aims. The quality of an organization can be represented and assessed using a four-part model of structure, process, output and outcome [Figure 1]. Each of the four aspects of quality assessment interact, e.g. good structure increases the likelihood of good process, and good process increases the likelihood of good outcome. [2]
It can be useful to collect and reflect on process and output data, e.g. the time between referral and a patient being seen, or the number of referrals to a service, in order to demonstrate or understand the demand for services and practical issues of meeting that demand. However, while assessing how many home care visits are made on each day, or how many patients are seen in a month may provide useful information about how a service is run, does not tell us anything about patients' or family members' experience of care (for example, having received home care, did the patient's pain improve?). Only assessing outcomes of care can provide this kind of information. The outcomes of care (i.e. (4.) in the model) are therefore of particular relevance in measuring quality, as they measure directly the relevance of care for patients, families and society as a whole.


 » What is Clinical Audit ? Top


Clinical audit is one way to measure quality in healthcare. It can be defined as the 'systematic critical analysis of the quality of clinical care including procedures used for diagnosis and treatment, the use of resources and resulting outcome and quality of life.' [3] In other words, clinical audit means a) looking at how well we currently perform something (e.g. pain management or psychological support), b) setting a target for how well we want to do it, c) deciding how we will make the improvement, d) putting this in place, and e) measuring again to see if we have achieved the target (see Box 1 for more details)-[Additional file 1]. Clinical audit is a cyclical activity, although this is often misunderstood: evaluation on its own is not audit, as the data collected are not used being used to inform changes in service provision which are implemented and evaluated. As Stephen Connor has said, 'Quality assessment must be tied to quality improvement'. [4] For service providers, this could mean conducting a clinical audit every year to make sure the service is always working to improve the care that is delivered. Clinical audit thus becomes a process of continuous improvement in the quality of care provided by a service, embedded within routine clinical practice and helping to bring about change for the better in terms of patient and family care. Because of its cyclical nature and the dynamism it brings to a healthcare organization, clinical audit has been described as its 'vital signs' or 'pulse', evidence that the organization is living rather than stagnating. [5]

Importantly, clinical audit is not a process of comparing one service with another and finding one or the other to be lacking in some way. Services will have different aims and philosophies, and, as Stjernswald says, 'You should not compare chocolate with mango'. [6] Clinical audit is ultimately about service providers being aware of the quality of their own service's care, including areas for potential improvement, and putting steps in place accordingly. The targets for improvement that services set themselves should reflect their stated aims as well as the areas of care currently requiring extra attention. Only when services are sufficiently similar in terms of their aims and the population cared for is comparison meaningful. In this instance, collecting data for audit does enable the effects of implementing different service models to be better understood. However, actual services will always be more complex than the service models they utilize, and should be considered in the context of the specific characteristics of the communities they serve. Clinical audit should not therefore be seen as a threat, but rather as a facilitator that enables more accurate reflection on service provision.


 » Outcomes in Palliative Care Top


Outcomes can be understood as any end result that is attributable to health service intervention, [7] where health is defined as a state of complete physical, mental (which may include spiritual) and social well-being and not merely the absence of disease or infirmity. [8] Clearly, this fits in well with the model of palliative care. In a general healthcare context, the outcome of primary interest is often morbidity; e.g. how many patients died from having an operation of type X at hospital Y in one year. Within palliative care, this aim is less relevant, as the focus of care shifts from extending life to improving the quality of life. A range of outcomes of relevance to palliative care arise out of the holistic aims of palliative care as stated, for example, by the World Health Organization (WHO) [9] (Box 2, also see [10] )-[Additional file 2]. Any of these outcomes would be an appropriate focus for measurement and improvement in a clinical audit, depending on the stated aims and priorities of the service.


 » Why Should Specialist Palliative Care Measure Outcomes of Care ? Top


Measuring the outcomes of palliative care has five main benefits. Firstly, it enables improvement of patient and family care on a holistic and individual basis. By obtaining more detailed information about the patient and family by using formal assessment methods in day-to-day practice, healthcare providers are able to tailor and improve their care on a case-by-case basis.

Secondly, assessing the outcomes of care in a formal way enables evidence to be gathered on the impact of care on the patient and family and the effectiveness of the service at meeting its aims. As palliative care is a relatively new specialty, it has much to prove! If systematically collected data is aggregated, analyzed and reviewed, it can be used as evidence of, for example, efficacy or cost-effectiveness. Through measuring the outcomes of care, studies in the US and UK have shown that palliative care improves quality of life, physical well being and symptoms including pain, spiritual well being and psychological well being. [11],[12],[13] Such evidence of effectiveness can be used to justify the continuation or expansion of services and secure resources for future services, e.g. by convincing potential funders. [14]
Thirdly, and most crucially in the context of this article, measuring outcomes is fundamental to clinical audit, enabling quality of care to be assessed and improved. Routine collection of data on the outcomes of care in diverse domains enables potential areas for improvement to be identified when the data are reviewed. Service managers can then utilize this data to improve practice, decide where resources should be focused, and set locally-relevant targets for quality of care for the future. Through ongoing audit the achievement of these targets can be monitored, and effective techniques to improve care can be shared with other services.

Fourthly, at the national level, measuring outcomes across a range of services builds an evidence base for setting quality standards and quality indicators appropriate and feasible for different types of service across India. Quality indicators (also called quality markers) are explicitly defined and measurable items referring to the outcomes, processes, or structure of care. [15] As quality indicators are adopted voluntarily, they offer a framework for a palliative care organization to define and track its progress against its own action plans. [16] In India, where quality indicators have not yet been set and service evaluation is at an embryonic stage, there is the chance to learn from omissions in developed countries, [17],[18] and ensure that cultural and spiritual aspects of palliative care, and the needs of family carers, are taken into account in national guidance and audit. Ultimately, national standards and quality indicators also need to be subjected to testing through well-designed trials. [19]

Finally, the most important reason to do audit is that patient and family have a right to quality care, matter where they receive care, how that care is delivered, or who delivers the care. Whether a patient is receiving care in a hospital or at home, from trained community volunteers or from medical personnel, the quality of care should be assessed, and the service provider should be committed to its improvement.


 » Clinical Audit in Indian Palliative Care Top


There has been some debate regarding the utility of conducting research, including service evaluation and audit, in developing country settings, where the funds used for such activities would, it is suggested, be better placed in feeding a hungry population. [20] However, in resource-limited contexts it is perhaps even more crucial that available resources, such as staff time and available funds, are used effectively, and that service development is evidence-based. [21],[22],[23] As Higginson and Bruera state, measurement and clinical audit are one way to minimize the risk of failure, learn at an early stage about potential problems, and identify successful strategies. [21] Without auditing the outcomes of care, some important domains of palliative care may be neglected. Costs of not conducting clinical audit include providing extra, inappropriate treatment, which wastes patients' and families' time as well as staff time and resources; providing underutilized or inappropriate services; uncontrolled symptoms which are distressing for patients and families, and may lead to delayed discharge or preventable emergency admissions; and other unresolved problems that may cause preventable suffering. [3] For example, research indicates that in the US and UK the needs of family members are often unmet. [24],[25],[26]Failure to audit family outcomes (such as family worry, confidence in caring for the patient, and adequacy of information received) may mean that they continue to be neglected. [27]

The need for evaluation and monitoring of quality of care in the Indian setting has been recognized by several authors writing in this journal. [1],[6],[28] Anil Kumar Paleri reports that the Pain and Palliative Care Policy of the Government of Kerala 'favors locally relevant audit and research at various levels for improving the programs and sharing useful experience. [29] Given the recognition of the importance of evaluation, what is now needed is a clear and concrete action plan, with a commitment from the Indian Association of Palliative Care (IAPC) and service providers to create the conditions necessary for clinical audit to be carried out across palliative care services in India. While there are organizational factors which facilitate successful audit [Box 3]-[Additional file 3], an essential first step is the selection of an outcome measurement tool.


 » Choosing an Outcome Measurement Tool Top


In the UK, a range of measures are used in palliative care service evaluation, the most common being the Support Team Assessment Schedule (STAS). [3],[27] However, many palliative care service managers report that they have developed their own assessment tools, or used more informal methods of evaluation such as staff meetings and daily log books. [27] A disadvantage of, using informal methods of assessing outcomes Is that it is difficult to set concrete and meaningful targets which reflect the experience of care by patients and families without inviting them to participate through the use of self-completion (or assisted completion) questionnaires. Using an assessment questionnaire developed in an informal way at your own service is also problematic, as the validity and reliability of the tool is unknown. Established tools used for audit and research purposes have undergone formal psychometric testing to ensure they are valid and reliable, i.e. measure what they set out to measure, and are appropriate in palliative care populations (for example, not too long and burdensome). The validation process aims to identify and eliminate problems in tools, such as systematic bias introduced by wording which leads the respondent to answer one way rather than another, or measurement inadequacies such as floor and ceiling effects. In addition to giving more accurate and valid results, the use of a validated and standardized outcome measurement tool across services means that results from sites with similar service models can be pooled, and results from services or service models with sufficiently similar aims can be meaningfully compared. This can contribute towards the setting of national quality standards, and may also eventually elucidate some of the strengths and weaknesses of specific service models. [4],[23]
In Africa, we were able to conduct audit as part of the Encompass project because of careful collaborative science beforehand to develop the APCA African Palliative Outcome Scale (POS). [33],[34] The APCA African POS was based on the Palliative Outcome Scale, a tool to assess quality of care that was originally developed and validated in the UK. [35],[36],[37] Working with the African Palliative Care Association (APCA) and services across Africa, this outcome measurement tool was developed and validated in a range of different settings, producing a tool that is tailored to and reliable in African palliative care. Services across the continent are therefore able to use the same tool in the knowledge that it is psychometrically valid and reflects their goals of care. Development of a similar tool in India is an essential task.

The use of a questionnaire such as the POS that is specifically designed to measure the quality of palliative care helps to ensure that a wide range of relevant outcomes are assessed. [38] A survey of palliative care services in Britain and Ireland found that although physical aspects of care were audited relatively frequently (by 61% of services), other core aspects of care were rarely audited, including bereavement care (17%), training (13%), and psychological and spiritual care (12%). [27] One of the reasons for this is that the latter domains are considered more difficult to assess formally than physical aspects of care. In the UK survey, 28% of services stated that difficulty of assessment was the reason for not auditing bereavement, 33% gave that response regarding psychological and spiritual care, and 15% regarding training. [27] However, well-validated measures do exist for the assessment of these more intangible concepts, such as quality of life, [39],[40] spiritual well being, [41],[42] the impact of training, [43],[44] and bereavement outcomes. [45],[46] As Charlton says, 'Unless these aspects are evaluated regularly, service providers cannot be confident they are successfully achieving their mission to promote optimal palliative care and, where possible, a good death'. [27]

Given the proliferation of palliative care outcome measures in recent years, it would beneficial to build on previous work and revalidate an existing measure in the Indian context. The choice of an appropriate tool would depend on the goals of the IAPC and the properties of the existing tools. However, it is important that the tool chosen for adaption and revalidation meets certain criteria [Box 4]- [Additional file 4].


 » Conclusion Top


Collaboration at regional, national and possibly international levels may be required in order to establish the necessary conditions for audit in India. Establishing relevant audit systems will require close interaction between local programs with specific needs and those with audit experience and methodological skills. [21] The development and validation of an Indian palliative care outcome measure will also necessarily be a collaborative process, in order to ensure that the resulting measure is applicable and appropriate across the subcontinent. However, there are also concrete steps that service providers can make in terms of staff education and training about quality improvement, prioritization of research and clinical audit, and collaboration with the IAPC and other services to ensure quality improvement remains high on the national agenda.

The IAPC has an important role to play in fostering increased service evaluation and improvement of existing services, [1] including supporting services conducting audit nationally. As a step towards this, the IAPC and Pallium India are to be congratulated for developing national standards for palliative care, reproduced in the Appendix to this paper. One of the desirable standards is that a palliative care service has a commitment to continuous quality improvement through ongoing use of a standardized audit tool (Point 34 [51] ). In order to meet this standard, the adaptation and validation of an appropriate outcome measurement tool is an essential next step, as recognized by the Declaration of Venice. [22] Only with such tools can relevant and applicable information regarding the effectiveness of palliative care in India be produced, and evidence-based standards and quality indicators be developed nationally.

 
 » References Top

1.Alexander J. Palliative care research and the IJPC. Indian J Palliat Care 2007;13:1-2.  Back to cited text no. 1    Medknow Journal  
2.Donabedian A. The quality of care: how can it be assessed. JAMA 1988;260:1743-8.  Back to cited text no. 2  [PUBMED]    
3.Higginson IJ. Clinical Audit in Palliative Care. Oxford, UK: Radcliffe Publishing; 1993.   Back to cited text no. 3      
4.Connor SR. Quality assessment and performance improvement in hospice and palliative care. Freedom from Pain. In: Bhatnagar S, editor. New Delhi: I. K. International; 2009. p. 178-82.  Back to cited text no. 4      
5.Bullock R. Clinical governance, the emperor's new clothes and the meaning of clinical audit. J Clin Excell 2002;4:43-6.  Back to cited text no. 5      
6.Stjernsward J. Coverage: Community participation in palliative care. Indian J Palliat Care 2005;11:111-7.  Back to cited text no. 6    Medknow Journal  
7.Department of Health (UK). On the state of the public health: the Annual Report of the Chief Medical Officer. London: HMSO; 1992.  Back to cited text no. 7      
8.Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19-22 June, 1946; signed on 22 July 1946 by the representatives of 61 States and entered into force on 7 April 1948. WHO; 2010. p. 100.  Back to cited text no. 8      
9.World Health Organisation. WHO definition of palliative care. World Health Organisation, 2006.  Back to cited text no. 9      
10.Working Party on Clinical Guidelines in Paliative Care. Outcome Measures in Palliative Care. London: National Council for Hospice and Specialist Palliative Care Services; 1995.  Back to cited text no. 10      
11.Cohen SR, Boston P, Mount BM, Porterfield P. Changes in quality of life following admission to palliative care units. Palliat Med 2001;15:363-71.  Back to cited text no. 11  [PUBMED]  [FULLTEXT]  
12.Goodwin DM, Higginson IJ, Myers K, Douglas HR, Normand CE. Effectiveness of palliative day care in improving pain, symptom control, and quality of life. J Pain Symptom Manage 2003;25:202-12.  Back to cited text no. 12  [PUBMED]  [FULLTEXT]  
13.Hearn J, Higginson IJ. Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Palliat Med 1998;12:317-32.  Back to cited text no. 13  [PUBMED]  [FULLTEXT]  
14.Menzies K, Murray J, Wilcock A. Audit of cancer pain management in a cancer centre. Int J Palliat N urs 2000;6:443-7.  Back to cited text no. 14      
15.Campbell SM, Braspenning J, Hutchinson A, Marshall MN. Research methods used in developing and applying quality indicators in primary care. BMJ 2003;326:816-9.  Back to cited text no. 15  [PUBMED]  [FULLTEXT]  
16.Department of Health (UK). End of Life Care Strategy: Quality Markers and measures for end of life care. Department of Health. 2009.  Back to cited text no. 16      
17.Pasman HR, Brandt HE, Deliens L, Francke AL. Quality indicators for palliative care: a systematic review. J Pain Symptom Manage 2009;38:145-56.  Back to cited text no. 17  [PUBMED]  [FULLTEXT]  
18.Seow H, Snyder CF, Shugarman LR, Mularski RA, Kutner JS, Lorenz KA, Developing quality indicators for cancer end-of-life care: proceedings from a national symposium. Cancer 2009;115:3820-9.  Back to cited text no. 18      
19.Seow H, Snyder CF, Mularski RA, Shugarman LR, Kutner JS, Lorenz KA, et al. A framework for assessing quality indicators for cancer care at the end of life. J Pain Symptom Manage 2009;38:903-12.  Back to cited text no. 19  [PUBMED]  [FULLTEXT]  
20.Merriman A, Kaur M. Palliative care in Africa: an appraisal. Lancet 2005;365:1909-11.  Back to cited text no. 20  [PUBMED]  [FULLTEXT]  
21.Higginson IJ, Bruera E. Do we need palliative care audit in developing countries? Palliat Med 2002;16:546-7.  Back to cited text no. 21  [PUBMED]  [FULLTEXT]  
22.International Association for Hospice and Palliative Care. The Declaration of Venice: palliative care research in developing countries. J Pain Palliat Care Pharmacother 2007;21:31-3.  Back to cited text no. 22  [PUBMED]    
23.Pampallona S, Bollini P. Palliative care in developing countries: why research is needed. J Pain Palliat Care Pharmacother 2003;17:171-82.  Back to cited text no. 23  [PUBMED]    
24.Devery K, Lennie I, Cooney N. Health outcomes for people who use palliative care services. J Palliat Care 1999;15:5-12.  Back to cited text no. 24      
25.Johnston G, Abraham C. The WHO objectives for palliative care: To what extent are we achieving them? Palliat Med 1995;9:123-37.  Back to cited text no. 25  [PUBMED]    
26.Longman AJ, Atwood JR, Sherman JB, Benedict J, Shang TC. Care needs of home-based cancer patients and their caregivers. Cancer Nurs 1992;4:371-5.  Back to cited text no. 26      
27.Charlton R, Smith G, White D, Austin C, Pitts M. Audit tools for palliative care services: identification of neglected aspects of care. Am J Hosp Palliat Care 2002;19:397-402.  Back to cited text no. 27  [PUBMED]  [FULLTEXT]  
28.Graham F, Clark D. Definition and evaluation: developing the debate on community participation in palliative care. Indian J Palliat Care 2005;11:2-5.  Back to cited text no. 28    Medknow Journal  
29.Paleri AK. Showing the way forward: pain and palliative care policy of the Government of Kerala. Indian J Palliat Care 2008;14:51-4.  Back to cited text no. 29    Medknow Journal  
30.Cooper J, Pettifer A. Promoting ownership in palliative care audit. Int J Palliat Nurs 2004;10:119-22.  Back to cited text no. 30  [PUBMED]  [FULLTEXT]  
31.Higginson IJ, Hearn J, Webb D. Audit in palliative care: does practice change? Eur J Cancer Care (Engl) 1996;5:233-6.  Back to cited text no. 31  [PUBMED]    
32.Johnston G, Crombie IK, Davies HT, Alder EM, Millard A. Reviewing audit: barriers and facilitating factors for effective clinical audit. Qual Health Care 2000;9:23-36.  Back to cited text no. 32  [PUBMED]  [FULLTEXT]  
33.Harding R, Selman L, Agupio G, Dinat N, Downing J, Gwyther L, et al. Validation of a core outcome measure for palliative care in Africa: the APCA African Palliative Outcome Scale. Health Qual Life Outcomes 2010;8:10.  Back to cited text no. 33  [PUBMED]  [FULLTEXT]  
34.Powell RA, Downing J, Harding R, Mwangi-Powell F, Connor S; APCA. Development of the APCA African Palliative Outcome Scale. J Pain Symptom Manage 2007;33:229-32.  Back to cited text no. 34  [PUBMED]  [FULLTEXT]  
35.Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Qual Health Care 1999;8:219-27.  Back to cited text no. 35  [PUBMED]  [FULLTEXT]  
36.Higginson IJ, Donaldson N. Relationship between three palliative care outcome scales. Health Qual Life Outcomes 2004;2:68.  Back to cited text no. 36  [PUBMED]  [FULLTEXT]  
37.Higginson IJ, Hart S, Silber E, Burman R, Edmonds P. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care 2006;22:158-65.  Back to cited text no. 37      
38.Mino JC. Assessing the outcome of palliative care. Eur J Palliat Care 1999;6:203-5.  Back to cited text no. 38      
39.Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K. Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. Palliat Med 1997;11:3-20.  Back to cited text no. 39      
40.Cohen SR, Mount BM, Strobel MG, Bui F. The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 1995;9:207-19.  Back to cited text no. 40      
41.Peterman AH, Fitchett G, Brady MJ, Hernandez L, Cella D. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy-spiritual well-being scale (FACIT-Sp). Ann Behav Med 2002;24:49-58.  Back to cited text no. 41      
42.Steinhauser KE, Voils CI, Clipp EC, Bosworth HB, Christakis NA, Tulsky JA. "Are you at peace?": one item to probe spiritual concerns at the end of life. Arch Intern Med 2006;166:101-5.  Back to cited text no. 42      
43.Fife BL, Irick N, Painter JD. A comparative study of the attitudes of physicians and nurses toward the management of cancer pain. J Pain Symptom Manage 1993;8:132-9.  Back to cited text no. 43      
44.Griffie J, Weissman DE. Palliative medicine nurse preceptorship at the Medical College of Wisconsin. J Pain Symptom Manage 1996;12:360-3.  Back to cited text no. 44      
45.Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979;41:209-18.  Back to cited text no. 45      
46.Prigerson HG, Maciejewski PK, Reynolds CF 3rd, Bierhals AJ, Newsom JT, Fasiczka A, et al. Inventory of Complicated Grief: a scale to measure maladaptive symptoms of loss. Psychiatry Res 1995;59:65-79.  Back to cited text no. 46      
47.Koller M, Aaronson NK, Blazeby J, Bottomley A, Dewolf L, Fayers P, et al. Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer 2007;43:1810-20.  Back to cited text no. 47      
48.Medical Outcomes Trust. Trust introduces new translation criteria. Med Outcomes Trust Bull 1997;5:1-4.  Back to cited text no. 48      
49.Murtagh FE, Addington-Hall JM, Higginson IJ. The value of cognitive interviewing techniques in palliative care research. Palliat Med 2007;21:87-93.  Back to cited text no. 49      
50.Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.  Back to cited text no. 50      
51.IAPC. Indian Association for Palliative Care Standards for Palliative Care Providers. 2009.  Back to cited text no. 51